File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes

TitleNegative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes
Authors
Issue Date2019
PublisherSpringer Nature, published in association with Cancer Research UK. The Journal's web site is located at http://www.nature.com/bjc
Citation
British Journal of Cancer, 2019, v. 121 n. 8, p. 690-698 How to Cite?
AbstractBackground: Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) in endemic regions may have undetectable plasma EBV DNA. Methods: We prospectively recruited 518 patients with non-metastatic NPC and measured their pre-treatment plasma EBV DNA. The stage distribution and prognosis between pre-treatment plasma EBV DNA-negative (0–20 copies/ml) and EBV DNA-positive (>20 copies/ml) patients following radical treatment were compared. Results: Seventy-eight patients (15.1%) were plasma EBV DNA-negative, and 62 in this subset (12.0%) had 0 copy/ml. Only 23/78 (29.5%) plasma EBV DNA-negative patients with advanced NPC (stage III-IVA) had strong EBV encoded RNA (EBER) positivity (score 3) in their tumours compared to 342/440 (77.7%) EBV DNA-positive patients of the same stages (p < 0.001). Though EBV DNA-negative patients had more early-stage disease (p < 0.001) and smaller volumes of the primary tumour and the positive neck nodes (p < 0.001), they had similar 5-year overall survival and cancer-specific survival to those EBV DNA-positive counterparts by stage. Similar results were also seen when plasma EBV DNA cut-off was set at 0 copy/ml. Conclusions: Patients with low-volume NPC may not be identified by plasma/serum tumour markers and caution should be taken in its utility as a screening tool for NPC even in endemic regions. Clinical trial registration: Clinicaltrials.gov Identifier: NCT02476669.
Persistent Identifierhttp://hdl.handle.net/10722/284045
ISSN
2023 Impact Factor: 6.4
2023 SCImago Journal Rankings: 3.000
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorNicholls, JM-
dc.contributor.authorLee, VHF-
dc.contributor.authorChan, SK-
dc.contributor.authorTsang, KC-
dc.contributor.authorChoi, CW-
dc.contributor.authorKwong, DLW-
dc.contributor.authorLam, KO-
dc.contributor.authorChan, SY-
dc.contributor.authorTong, CC-
dc.contributor.authorSo, TH-
dc.contributor.authorLeung, TW-
dc.contributor.authorLuk, MY-
dc.contributor.authorKhong, PL-
dc.contributor.authorLee, AWM-
dc.date.accessioned2020-07-20T05:55:39Z-
dc.date.available2020-07-20T05:55:39Z-
dc.date.issued2019-
dc.identifier.citationBritish Journal of Cancer, 2019, v. 121 n. 8, p. 690-698-
dc.identifier.issn0007-0920-
dc.identifier.urihttp://hdl.handle.net/10722/284045-
dc.description.abstractBackground: Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) in endemic regions may have undetectable plasma EBV DNA. Methods: We prospectively recruited 518 patients with non-metastatic NPC and measured their pre-treatment plasma EBV DNA. The stage distribution and prognosis between pre-treatment plasma EBV DNA-negative (0–20 copies/ml) and EBV DNA-positive (>20 copies/ml) patients following radical treatment were compared. Results: Seventy-eight patients (15.1%) were plasma EBV DNA-negative, and 62 in this subset (12.0%) had 0 copy/ml. Only 23/78 (29.5%) plasma EBV DNA-negative patients with advanced NPC (stage III-IVA) had strong EBV encoded RNA (EBER) positivity (score 3) in their tumours compared to 342/440 (77.7%) EBV DNA-positive patients of the same stages (p < 0.001). Though EBV DNA-negative patients had more early-stage disease (p < 0.001) and smaller volumes of the primary tumour and the positive neck nodes (p < 0.001), they had similar 5-year overall survival and cancer-specific survival to those EBV DNA-positive counterparts by stage. Similar results were also seen when plasma EBV DNA cut-off was set at 0 copy/ml. Conclusions: Patients with low-volume NPC may not be identified by plasma/serum tumour markers and caution should be taken in its utility as a screening tool for NPC even in endemic regions. Clinical trial registration: Clinicaltrials.gov Identifier: NCT02476669.-
dc.languageeng-
dc.publisherSpringer Nature, published in association with Cancer Research UK. The Journal's web site is located at http://www.nature.com/bjc-
dc.relation.ispartofBritish Journal of Cancer-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleNegative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes-
dc.typeArticle-
dc.identifier.emailNicholls, JM: jmnichol@hkucc.hku.hk-
dc.identifier.emailLee, VHF: vhflee@hku.hk-
dc.identifier.emailChoi, CW: hcchoi@hku.hk-
dc.identifier.emailKwong, DLW: dlwkwong@hku.hk-
dc.identifier.emailLam, KO: lamkaon@hku.hk-
dc.identifier.emailTong, CC: tccz01@hku.hk-
dc.identifier.emailSo, TH: sth495@hku.hk-
dc.identifier.emailLeung, TW: ltw920@hkucc.hku.hk-
dc.identifier.emailLuk, MY: myluk@hkucc.hku.hk-
dc.identifier.emailKhong, PL: plkhong@hku.hk-
dc.identifier.emailLee, AWM: awmlee@hkucc.hku.hk-
dc.identifier.authorityNicholls, JM=rp00364-
dc.identifier.authorityLee, VHF=rp00264-
dc.identifier.authorityKwong, DLW=rp00414-
dc.identifier.authorityLam, KO=rp01501-
dc.identifier.authoritySo, TH=rp01981-
dc.identifier.authorityKhong, PL=rp00467-
dc.identifier.authorityLee, AWM=rp02056-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1038/s41416-019-0575-6-
dc.identifier.pmid31527689-
dc.identifier.pmcidPMC6888810-
dc.identifier.scopuseid_2-s2.0-85073310068-
dc.identifier.hkuros311326-
dc.identifier.volume121-
dc.identifier.issue8-
dc.identifier.spage690-
dc.identifier.epage698-
dc.identifier.isiWOS:000490189300008-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0007-0920-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats